Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03900689 · ClinicalTrials.gov registry record
Social Determinants of Health in Glioblastoma Population
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 100
- Enrollment target
NCT03900689: Completed study, sponsored by Wake Forest University Health Sciences.
NCT03900689 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03900689 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
The overall aim of this study is to prospectively characterize social health disparities in a cross-sectional cohort of glioma patients with attention to exploring and thematically categorizing the patient-specific and community-level factors. This will be conducted in two parts.
Primary Outcome
A 21 question questionnaire to collect data based on five main social determinants of health (education, economic status, neighborhood/surrounding environment, health and healthcare, community involvement). The questionnaire is comprised of Yes or No answers, multiple choice questions and Likert scale questions (not at all to quite a bit). This will be completed in Part 1 of the study.
Interventions
- OTHER Part 1 Survey Group
- OTHER Part 2 Focus Group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-05-22 |
| Est. Completion | 2022-03-27 |
What the finished NCT03900689 record still lists
NCT03900689 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Part 1 Survey Group is the first listed.
NCT03900689 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03900689 about?
NCT03900689 is a clinical study titled "Social Determinants of Health in Glioblastoma Population". The overall aim of this study is to prospectively characterize social health disparities in a cross-sectional cohort of glioma patients with attention to exploring and thematically categorizing the patient-specific and community-level factors. This will be conducted in two parts.
What is the current status of trial NCT03900689?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2019-05-22. Estimated completion is 2022-03-27.
What interventions are being tested in trial NCT03900689?
The interventions under investigation include: Part 1 Survey Group (OTHER), Part 2 Focus Group (OTHER).
Who is sponsoring clinical trial NCT03900689?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI